THE WOODLANDS, TX — January 9, 2026 — Leads & Copy — Autonomix Medical, Inc. (NASDAQ: AMIX) has announced new subgroup clinical data from its Proof-of-Concept (PoC) study, presented at the 2026 ASCO Gastrointestinal (GI) Cancers Symposium, demonstrating significant pain relief in pancreatic cancer patients across all disease stages.
The analysis, which expands on previously reported data from the company’s ongoing clinical evaluation, examines outcomes by pancreatic cancer stage in patients treated for severe pancreatic cancer-related pain. The post hoc subgroup analysis evaluates pancreatic cancer patients with severe baseline pain treated using a transvascular RF denervation platform. Outcomes were stratified by cancer stage, from Stage 2 through Stage 4.
Key findings of the study include:
- Rapid onset effect: Responding patients showed a marked reduction in average pain within 24 hours following the procedure.
- Early clinical impact: At 7-days post-procedure, 93.75% of responding patients (N=16) improved from severe pain to mild or moderate pain, with some achieving near-elimination levels of pain.
- Sustained benefit: At 4–6-weeks post-procedure, approximately two-thirds of responding patients (N=9) maintained pain at mild or elimination levels.
- Durability through 3 months: At 3-months post-procedure, no responding patients (N=6) reported severe pain, and 50% maintained mild or eliminated pain levels.
- Late-stage disease: Meaningful improvement was observed even among late-stage (Stage 4) cancer patients.
Brad Hauser, President and Chief Executive Officer of Autonomix Medical, stated that pancreatic cancer pain remains one of the most debilitating and undertreated aspects of oncology care. He added that seeing patients move from severe pain to mild or near-elimination levels of pain, even in the most advanced stages of pancreatic cancer, is extraordinarily encouraging. He believes that a targeted, nerve-based approach has the potential to provide meaningful relief when traditional pharmacologic and interventional options fall short.
The subgroup findings were presented as part of Autonomix’s poster entitled “Pain mitigation in pancreatic adenocarcinoma: A long-term analysis of denervation via transvascular RF energy-based ablation” during Poster Session B at ASCO GI 2026. The abstract number is 693. The presenter was Robert S. Schwartz, MD, Chief Medical Officer of Autonomix Medical, Inc.
Autonomix Medical, Inc. focuses on advancing innovative technologies to revolutionize how diseases involving the nervous system are diagnosed and treated. The company’s platform system technology includes a catheter-based microchip sensing array that may have the ability to detect and differentiate neural signals with greater sensitivity than currently available technologies. The company is initially developing this technology for the treatment of pain, with initial trials focused on pancreatic cancer.
Jenene Thomas
908.824.0775
autonomix@jtcir.com
Source: Autonomix Medical, Inc.
